Why Novavax Shares Are Rising

Novavax, Inc. NVAX shares are trading higher after the company announced it filed for authorization of its COVID-19 vaccine in the UK.

Novavax says the company's application for Conditional Marketing Authorization (CMA) marks the first submission for authorization of a protein-based COVID-19 vaccine in the United Kingdom.

Novavax is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. Novavax works together with its wholly-owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats.

Novavax has a 52-week high of $331.68 and a 52-week low of $76.58.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: Newswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!